Crown Bioscience opens new US model development centre
Iona Everson | September 19, 2025 | News story | Medical Communications, Research and Development | CRO, biotech, crown bioscience, life sciences
Crown Bioscience, a US global contract research organisation (CRO) that is part of JSR Life Sciences and Japan-based JSR Corporation, has opened a model development centre in North Carolina, US.
The investment expands the company’s operations and its ability to deliver advanced preclinical oncology models, including patient-derived xenografts (PDX), PDX warm models, PDX-derived organoids (PDXO), and patient-derived organoids (PDO), to meet the evolving needs of pharmaceutical and biotechnology companies.
As regulatory frameworks shift and precision medicine continues to evolve, the demand for innovative, scalable, translatable, and ethically-aligned models supporting current drug development within the market is growing and the new facility will provide localised access to global scientific expertise and preclinical services.
Focused on advancing clinically relevant oncology models, the new site will support Crown Bioscience’s model platform portfolio through collaboration with its other facilities. It will also accelerate the adoption of 3D cell culture and organoid technologies in response to key industry developments.
The site, due to be fully operational next month, will include roles in oncology research, study management and laboratory operations, creating new opportunities for local talent and attracting scientific expertise to the region.
John Gu, CEO of Crown Bioscience, said the new facility is “a catalyst for how we serve the next generation of oncology research” and that “its location and capabilities allow us to accelerate project timelines and foster closer scientific collaboration”.
This article featured in: October 2025 – The Pharmafile Brief
Related Content
Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
